Pipeline Watch: 16 Japanese Approvals And Nine Phase III Trial Readouts
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The table above records the past week's changes to the progress of selected potential new products through the clinical trial pipeline, using data from Informa Pharma Intelligence's Biomedtracker. It lists drugs for which an important event was recorded between 25 and 31 March, divided by event type.
Hyperlinks in the table take subscribers to the relevant event section of Biomedtracker where more details can be found, or to articles on the Scrip website where the results of clinical trials, or details of an approval, are explored and analyzed.
Events can include Phase II and Phase III clinical trial initiations and the release of top-line and updated clinical trial results.
The change to Biomedtracker's Likelihood of Approval (LOA) metric, and the new LOA, are also included as a percentage for products where available. The LOA is based on Biomedtracker's view of the historical progress of drugs developed within a particular disease sector, combined with an opinion of its analysts.
A brief summary of product approvals, and new indications, from around the world are also included. Make use of the tabs, scroll button and search function to see each section.
A companion resource, the Pink Sheet's regulatory-focused FDA Performance Tracker, follows regulatory milestones such as marketing submissions, approvals, user fee dates, and complete response letters.